Enhanced potency of replicon vaccine using one vector to simultaneously co-express antigen and interleukin-4 molecular adjuvant

Ma, Yao; An, Huaijie; Wei, Xiao-Qi; Chen, Nansheng; Yu, Yun-Zhou; Sun, Zhiwei

doi:10.4161/hv.22888

Cited by 9 publications

(4 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chemokine-antigen fusion is not a novel strategy for the design and optimization of DNA vaccine constructs. Compared with co-administration of the chemokine and antigen on separate vectors, coexpression from the same vector is a more effective immunization strategy [20,[28][29][30], since it provides a more conducive microenvironment for targeting the antigen to chemokine receptors on professional APCs by linking antigen and chemokine expression closely in vivo. The effects of coexpression of the antigen and chemokine on DNA vaccine responses require further investigation.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Co-administration of antigen with chemokine MCP-3 or MDC/CCL22 enhances DNA vaccine potency

Xie

Wang²,

Yang³

et al. 2015

Invest New Drugs

View full text Add to dashboard Cite

We evaluated the utility of chemokine MCP-3 and MDC/CCL22 as molecular adjuvants of DNA vaccines for botulinum neurotoxin serotype A (BoNT/A) in a Balb/c mouse model. Notably, the immunogenicity of the DNA vaccine against BoNT/A was not enhanced using a fusion of the AHc-C antigen with the MCP-3 or MDC/CCL22. Nevertheless, the potency of the DNA vaccine was significantly modulated and enhanced by co-administration of the AHc-C antigen with MCP-3 or MDC/CCL22. This strategy elicited high levels of humoral immune responses and protection against BoNT/A. The enhanced potency was further boosted by co-administration of the AHc-C antigen with both MCP-3 and MDC/CCL22 in Balb/c mice, but not by co-administration of AHc-C antigen with the MCP-3-MDC/CCL22 fusion. Co-immunization with both the MCP-3 and MDC/CCL22 constructs induced the highest levels of humoral immunity and protective potency against BoNT/A. Our results indicated that MCP-3 and MDC/CCL22 are effective molecular adjuvants of the immune responses induced by the AHc-C-expressing DNA vaccine when delivered by co-administration of the individual chemokines, but not when delivered in the form of a chemokine/antigen fusion. Thus, we describe an alternative strategy to the design and optimization of DNA vaccine constructs based on co-administration of the antigen with the chemokine rather than in the form of a chemokine/antigen fusion.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Anti-AHc-C antibodies in the sera from mice in the different groups were detected by ELISA as described previously [19,20]. Briefly, ELISA plates (Corning) were coated overnight at 4°C with 100 μl recombinant AHc-C (2 μg/ml).…”

Section: Detection Of Anti-ahc-c Antibodies In Serummentioning

confidence: 99%

Co-administration of antigen with chemokine MCP-3 or MDC/CCL22 enhances DNA vaccine potency

Xie

Wang²,

Yang³

et al. 2015

Invest New Drugs

View full text Add to dashboard Cite

show abstract

“…IRES is also used to create vectors encoding antigens and an immunomodulating agent to modulate immunogenicity. The use of a bicistronic vector encoding Hc gene of botulinum neurotoxin serotype A (BoNT/A) and interleukin 4 (IL-4) gene via IRES has significantly increased the anti-AHc antibody titers, serum neutralization titers, and survival rates of immunized mice [102].…”

Section: Multicistronic Vectors For the Prevention Of Viral And Bamentioning

confidence: 99%

Production and Application of Multicistronic Constructs for Various Human Disease Therapies

et al. 2019

View full text Add to dashboard Cite

The development of multicistronic vectors has opened up new opportunities to address the fundamental issues of molecular and cellular biology related to the need for the simultaneous delivery and joint expression of several genes. To date, the examples of the successful use of multicistronic vectors have been described for the development of new methods of treatment of various human diseases, including cardiovascular, oncological, metabolic, autoimmune, and neurodegenerative disorders. The safety and effectiveness of the joint delivery of therapeutic genes in multicistronic vectors based on the internal ribosome entry site (IRES) and self-cleaving 2A peptides have been shown in both in vitro and in vivo experiments as well as in clinical trials. Co-expression of several genes in one vector has also been used to create animal models of various inherited diseases which are caused by mutations in several genes. Multicistronic vectors provide expression of all mutant genes, which allows the most complete mimicking disease pathogenesis. This review comprehensively discusses multicistronic vectors based on IRES nucleotide sequence and self-cleaving 2A peptides, including its features and possible application for the treatment and modeling of various human diseases.

show abstract

“…In order to enhance immunity, cytokines genes such as IL-4 have been included into thirdgeneration vaccines (DNA vaccines) and have demonstrated to evoke a Th2-type response [67]. Interestingly, porcine IL-4 has been successfully evaluated as an immunological adjuvant in a vaccine candidate against porcine reproductive and respiratory syndrome virus (PRRSV) [68].…”

Section: Adjuvantsmentioning

confidence: 99%

Vaccination against Trichinella spiralis: Potential, Limitations and Future Directions

Andrade-Becerra¹,

Pompa-Mera²,

MaríaRibas-Aparicio³

et al. 2017

Natural Remedies in the Fight Against Parasites

View full text Add to dashboard Cite

Trichinellosis is a food-borne parasitic disease caused by round worms of the genus Trichinella. The majority of human outbreaks are attributed to consumption of raw or undercooked pork meat contaminated with T. spiralis muscle larvae. A blockingtransmission vaccine against trichinellosis will allow preventing swine infection and will contribute to disease control. In this chapter, different vaccine candidates so far developed against T. spiralis, including first-, second-, and third-generation vaccines, are discussed. Most vaccine candidates are based on a unique antigen mainly from the muscle larva stage, inducing with some exceptions, partial protection although a mix Th1/Th2 immune response is elicited. Therefore, the need for identification of new antigens from different parasite stages focusing on infective intestinal larvae, adult, and newborn larvae stages as well as the evaluation of their protective capacity in pigs is presented. The design of multi-epitope vaccines and the use of adjuvants or immunomodulatory molecules capable to polarize the immune response to a Th2-type-protective response are discussed as imperative elements of modern vaccines. Plant-based vaccines and probiotics as excellent tools for vaccine development against T. spiralis are also presented as an attractive platform for veterinary vaccines.

show abstract

Enhanced potency of replicon vaccine using one vector to simultaneously co-express antigen and interleukin-4 molecular adjuvant

Cited by 9 publications

References 39 publications

Co-administration of antigen with chemokine MCP-3 or MDC/CCL22 enhances DNA vaccine potency

Co-administration of antigen with chemokine MCP-3 or MDC/CCL22 enhances DNA vaccine potency

Production and Application of Multicistronic Constructs for Various Human Disease Therapies

Vaccination against Trichinella spiralis: Potential, Limitations and Future Directions

Contact Info

Product

Resources

About